electroCore (ECOR)
Makes prescription and consumer devices using non-invasive vagus-nerve stimulation.
Something off on this page? Send us feedback.
Sells prescription gammaCore and Quell products alongside Truvaga and TAC-STIM consumer devices. The portfolio applies non-invasive vagus-nerve stimulation to care, general wellness, and human performance.
Commercializes non-invasive vagus-nerve-stimulation products across prescription care and consumer wellness. gammaCore and Quell Fibromyalgia are the leading commercial products, while Truvaga and TAC-STIM are handheld personal-use offerings for general wellness and human performance. The group operates a multi-product medicine-and-wellness portfolio.
The portfolio combines regulated prescription products with consumer products, so claims and routes to market differ by line. U.S. operations are based in Rockaway, New Jersey, with European sales supported by electroCore U.K. Ltd. The business depends on non-invasive bioelectronic technology and on regulatory clearance and competitive alternatives across its markets.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.0M · Total debt $9.6M · Total assets $17.1M · Shareholders' equity −$2.8M
- Revenue
- $9.5M
- Operating income
- −$2.8M
- Net income
- −$3.1M
No dividends on record.
| Institutions32 holders · as of Jun 30, 2026 | 11.40% | 1.03M shares | |
| Insiders12 holders · as of Aug 25, 2026 | 25.59% | 2.31M shares | |
| Strategic holders1 holder · as of May 5, 2026 | 5.74% | 517.5K shares | |
| Otherremainder | 57.27% | 5.16M shares |
9.02M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Tianyi ZhangInsider | 8.15% | 734,638 | 13Gfiled Jun 5, 2025 ↗ |
Hilve Holdings LtdStrategic | 5.74% | 517,522 | 13Gfiled May 5, 2026 ↗ |
AWM Investment Company, Inc.Institution | 5.65% | 509,100 | 13Gfiled Nov 13, 2025 ↗ |
Charles Steve TheofilosInsiderdirector | 4.93% | 444,530 | 13Gfiled Jul 9, 2025 ↗ |
Thomas J. ErricoInsiderdirector | 3.81% | 343,332 | Form 4filed Aug 17, 2026 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Joshua S. Lev | officer: CFO and Interim President | −3,000 | $9.36 |
| Aug 24, 2026 | Joshua S. Lev | officer: CFO and Interim President | −5,000 | $9.88 |
| Aug 21, 2026 | Joshua S. Lev | officer: CFO and Interim President | −12,000 | $10.22 |
| Aug 13, 2026 | Thomas J. Errico | director | +5,000 | $9.85 |
| Apr 23, 2026 | Daniel S. Goldberger | other: Former Officer & Director | −80,000 | $6.80 |
